NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
23 mai 2017 07h00 HE
|
NeuroDerm Ltd.
- ND0612 head-to-head pilot PK results and ND0701 first-in-man PK results to also be presented - - ND0612 clinical data featured in four additional abstracts - REHOVOT, Israel, May 23, 2017 (GLOBE...
NeuroDerm Announces First Quarter 2017 Financial Results
11 mai 2017 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
20 avr. 2017 11h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm to Host Investor Day on April 21, 2017
10 avr. 2017 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, April 10, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
30 mars 2017 07h00 HE
|
NeuroDerm Ltd.
Files Annual Report on Form 20-F Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a...
NeuroDerm to Host Fourth Quarter and 2016 Fiscal Year Financial Results Conference Call on March 30, 2017
21 mars 2017 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, March 21, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS)...
NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson’s Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting
01 mars 2017 07h00 HE
|
NeuroDerm Ltd.
- Trial 006 demonstrated a statistically significant and clinically meaningful reduction in OFF-time and increase in proportion of patients “ON” by 8:00 am (primary and key secondary endpoints) - -...
NeuroDerm CEO to Present at Upcoming Investor Conferences
27 févr. 2017 16h01 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Feb. 27, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Extraordinary General Meeting of Shareholders
26 janv. 2017 16h01 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 12, 2017
03 janv. 2017 07h00 HE
|
NeuroDerm Ltd.
REHOVOT, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...